venlafaxin krka 75 mg
krka sverige ab - venlafaksinhydroklorid - depotkapsel, hard - 75 mg
venlafaxin ratiopharm 37.5 mg
ratiopharm gmbh - venlafaksinhydroklorid - depotkapsel, hard - 37.5 mg
venlazid 150 mg
medical valley invest ab - venlafaksinhydroklorid - depottablett - 150 mg
venlazid 75 mg
medical valley invest ab - venlafaksinhydroklorid - depottablett - 75 mg
venlazid 225 mg
medical valley invest ab - venlafaksinhydroklorid - depottablett - 225 mg
venlix 37.5 mg
ratiopharm gmbh - venlafaksinhydroklorid - tablett - 37.5 mg
lorviqua
pfizer europe ma eeig - lorlatinib - karsinom, ikke-småcellet lunge - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
sertraline accord 50 mg
accord healthcare b.v. - sertralinhydroklorid - tablett, filmdrasjert - 50 mg
sertraline accord 100 mg
accord healthcare b.v. - sertralinhydroklorid - tablett, filmdrasjert - 100 mg
vitrakvi
bayer ag - larotrectinib sulfat - abdominal neoplasmer - antineoplastiske midler - vitrakvi som monoterapi er indisert for behandling av voksne og paediatric pasienter med solide svulster som viser en neurotrophic reseptor tyrosin kinase (ntrk) - genet fusion,som har en sykdom som er lokalt avansert eller metastatisk hvor kirurgisk reseksjon er sannsynlig å resultere i alvorlig sykelighet, andwho har ingen tilfredsstillende behandlingstilbud.